|
KMID : 1011720190120020127
|
|
International Journal of Thyroidology
2019 Volume.12 No. 2 p.127 ~ p.131
|
|
|
A Case of Severe Pneumocystis Pneumonia in a Thyroid Cancer Patient Receiving Lenvatinib
|
|
Jin Mei Hua
Kim Won-Gu
Kim Tae-Yong
Kim Won-Bae
Shong Young-Kee
Jeon Min-Ji
|
|
|
Abstract
|
|
|
|
Lenvatinib is a multitargeted tyrosine kinase inhibitor approved for use in patients with iodine-131?refractory thyroid cancer. The common adverse events of lenvatinib include hypertension, proteinuria, fatigue, and diarrhea. To date, no report on Pneumocystis pneumonia (PCP) in patients receiving lenvatinib has been published. Here, we present a case of severe PCP that led to the death of a 79-year-old woman who was diagnosed with poorly differentiated thyroid cancer and received lenvatinib. The development of PCP should be considered when patients taking lenvatinib show clinical symptoms of pneumonia, and regular chest X-ray follow-up is needed for patients receiving lenvatinib.
|
|
|
KEYWORD
|
|
|
Lenvatinib, Pneumocystis pneumonia, Interstitial pneumonia, Thyroid cancer
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
 
|